Neutralase heparin neutralizer: IBT announced interim results of its Phase II trial of Neutralase to neutralize heparin's anticoagulant effect during surgery in

Ibex Technologies Inc. (TSE:IBT), Montreal, Quebec
Product: Neutralase heparin

Read the full 96 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE